Startups Manhattan Genomics, Preventive Revive CRISPR Baby Debate

A New Chapter in a Controversial Story

Six years after scientist He Jiankui shocked the world by creating the first gene-edited babies, two little-known biotech startups are reopening one of biology's most fraught frontiers. Manhattan Genomics and Preventive have both signaled plans to pursue heritable genome editing in human embryos, a move that has quickly reignited the ethical firestorm that followed He's experiment in 2018 1. That earlier episode ended in international condemnation and legal consequences for He, and it left the scientific community wary of any effort to edit DNA in ways that would be passed down to future generations 1.

Why This Reignites Old Fears

The core concern with heritable, or "germline," editing is that changes made to an embryo's genome are not confined to one patient — they are inherited by all future descendants, with consequences that cannot be undone or fully predicted. He Jiankui's work was widely rejected by scientists and regulators precisely because the safety, consent, and long-term societal implications were considered too poorly understood to proceed. That the same territory is now being approached by commercial startups, rather than a single rogue academic, raises new questions about oversight, funding incentives, and whether venture-backed timelines are compatible with the caution such research demands 1.

A Biotech Sector in Flux

The embryo-editing news lands amid a broader, uneven moment for biotech as an industry. On the financial side, sentiment has been notably upbeat: JPMorgan has pointed to a resurgence in biotech investment as a tailwind for companies like Charles River Laboratories, which supports drug research and development 2. Fund managers are also capitalizing on the rally — the Franklin Biotechnology Discovery fund has posted a 13% five-year annualized return, more than double that of a leading biotech index ETF, underscoring investor appetite for the sector 3. Real-time market trackers have likewise been highlighting a steady stream of FDA approvals, clinical trial results, and other catalysts moving biotech and pharma stocks 4.

Yet the industry's momentum is far from uniform. Moderna's stock swung sharply after positive trial results for a cancer vaccine sent shares surging before investors pulled back, reflecting how quickly enthusiasm can reverse even on genuinely encouraging data 6. Meanwhile, layoffs continue to ripple through the sector: one major Bay Area biotech company has cut another 103 jobs, marking its fifth round of layoffs since mid-2025 and adding to concerns about financial pressure even at large, established firms 5.

The Bigger Picture

Taken together, the coverage paints a picture of an industry pulled in two directions at once — a Wall Street narrative of rallying stocks and renewed investment enthusiasm, and a scientific narrative confronting one of its thorniest ethical dilemmas anew. Whether Manhattan Genomics and Preventive move forward with actual embryo-editing experiments, and how regulators respond, will likely shape not just the future of germline editing but also public and investor trust in a biotech sector still working to define its next era of growth.